| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| CHAMBLISS, BAHNER & STOPHEL, P.C. | 8,531 | 4,266 | 4,265 |
| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| PARTNERSHIP FLOWTHROUGH - UBI SHORT-TERM | PURCHASED | 6,326 | 0 | -6,326 | ||||||
| PARTNERSHIP FLOWTHROUGH - UBI - LONG-TERM | PURCHASED | 8,233 | 0 | 8,233 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| DONOR ADVISED FUNDS | FORM 990-PF, PART VII-A, LINE 12 | NO DISTRIBUTIONS WERE MADE TO OUR DONOR ADVISED FUND AT CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION (DBA THE GENEROSITY TRUST), EIN# 62-1536731 DURING THE 2018 TAX YEAR. THE TRUST RETAINED ADVISORY PRIVILEGES. CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION ("CCCF") IS A SECTION 509(A)(1) ORGANIZATION AS REFERRED TO IN SECTION 170(B)(1)(A)(VI). THE ENTIRE AMOUNT WAS TREATED AS A QUALIFYING DISTRIBUTION IN PART XV, LINE 3, CONTRIBUTIONS, GIFTS, GRANTS PAID. THE DONOR-ADVISED FUND AGREEMENT BETWEEN THE CHRISTIAN EDUCATION CHARITABLE TRUST AND CCCF INCLUDES THE FOLLOWING:"CCCF SHALL RECEIVE, REVIEW AND CONSIDER WRITTEN RECOMMENDATIONS FROM THE COMMITTEE CONCERNING GRANTS MADE FROM THE FUND AND ANY CONDITIONS WHICH SHOULD BE PLACED UPON SUCH GRANTS. THE FINAL DECISION CONCERNING SUCH MATTERS SHALL BE MADE BY THE BOARD OF DIRECTORS OF CCCF.""NO INCOME OR PRINCIPAL OF THE FUND SHALL BE USED FOR ANY PURPOSE OR PAID TO ANY BENEFICIARY IF SUCH USE OR PAYMENT WOULD NOT BE PERMITTED BY THE INTERNAL REVENUE CODE (THE "CODE") OR REGULATIONS THEREUNDER FOR AN ORGANIZATION DESCRIBED IN SECTION 501(C)(3) OF THE CODE, TO WHICH CONTRIBUTIONS ARE DEDUCTIBLE UNDER SECTION 170(C)(2) OF THE CODE." |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| NXTHERA, INC. | 0 | 924,824 |
| VERAN MEDICAL TECHNOLOGIES | 462,500 | 515,194 |
| ATLANTA CATHETER THERAPIES | 47,397 | 47,397 |
| COHERA MEDICAL | 1,570,375 | 0 |
| NXPHASE | 8,110 | 8,110 |
| AEGEA MEDICAL | 750,000 | 750,000 |
| PERSHING 1212 - SEE ATTACHED | 469,744 | 422,524 |
| PERSHING 1212 - SEE ATTACHED | 1,041,828 | 1,180,005 |
| PERSHING 1212 - SEE ATTACHED | 4,924,657 | 4,665,764 |
| ILLIANT CORPORATION 1,068 SHARES SERIES A PREFERRED | 2,136 | 0 |
| APHERESIS TECHNOLOGIES 74 SHARES | 6 | 0 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| AERIAL BIOPHARMA, LLC | AT COST | 198,395 | 68,070 |
| ALTUM CREDIT FUND, L.P. | AT COST | 2,140,771 | 2,091,744 |
| ARRIVO BIOVENTURES LLC | AT COST | 171,623 | 171,435 |
| BIOTECHNOLOGY VALUE FUND, L.P. | AT COST | 2,558 | 106 |
| BOW RIVER CAPITAL 2017-QP FUND, LP | AT COST | 76,466 | 86,683 |
| C-III RECOVERY FUND II LP | AT COST | 359,510 | 358,251 |
| CEVIAN CAPITAL II, L.P. | AT COST | 1,068,257 | 1,012,312 |
| DYNAMO FUND I, LP | AT COST | 135,259 | 184,089 |
| FULCRUM GROWTH FUND III QP, LLC | AT COST | 182,913 | 182,527 |
| GCM GROSVEOR MACLELLAN INVESTMENT FUND LP | AT COST | 187,774 | 245,092 |
| H2OEY VENTURES | AT COST | 95,310 | 95,310 |
| KW STRATUS LLC | AT COST | 217,097 | 217,097 |
| MIDNIGHT PHARMA LLC | AT COST | 15,395 | 12,609 |
| PORTFOLIO ADVISORS SECONDARY FUND III, L.P. | AT COST | 196,475 | 221,785 |
| PS INSTITUTIONAL ONSHORE LP | AT COST | 669,416 | 660,468 |
| RELEVANCE CAPITAL III, LP | AT COST | 284,713 | 284,223 |
| RENAISSANCE INSTITUTIONAL EQUITIES FUND LLC | AT COST | 1,523,538 | 1,706,367 |
| RESOLUTE CAPITAL PARTNERS FUND IV, LP | AT COST | 123,882 | 123,882 |
| RIVER VII LP | AT COST | 141,116 | 130,731 |
| SIGNIA VENTURE PARTNERS III, LP | AT COST | 15,910 | 15,347 |
| TENTH STREET FINANCIAL OPPORTUNITY FUND I, L.P.2 | AT COST | 96,641 | 96,641 |
| TENTH STREET FINANCIAL OPPORTUNITY FUND II LP | AT COST | 172,623 | 172,623 |
| VALOR VENTURE FUND II, L.P. | AT COST | 333,553 | 333,553 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| RECEIVABLES ON SALE OF INVESTMENTS | 908,026 | 692,667 | 692,667 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| PARTNERSHIPS PORTFOLIO DEDUCTIONS | 265 | 265 | 0 | |
| TECHNOLOGY | 4,290 | 215 | 4,075 | |
| CONSULTING EXPENSE | 42,044 | 0 | 42,044 | |
| INSURANCE | 1,395 | 70 | 1,325 | |
| TRAINING | 1,799 | 0 | 1,799 | |
| OFFICE EXPENSE | 1,587 | 79 | 1,508 | |
| GUEST EXPENSE AND MEALS | 1,288 | 0 | 1,288 | |
| BOARD AND TRUSTEE EXPENSES | 1,509 | 0 | 1,509 | |
| PARTNERSHIPS PORTFOLIO DEDUCTIONS | 29,183 | 29,183 | 0 | |
| OTHER PARTNERSHIPS DEDUCTIONS | 193,120 | 193,120 | 0 | |
| INVESTMENT AND MANAGEMENT FEES | 45,735 | 45,735 | 0 | |
| OTHER MISC | 412 | 412 | 0 | |
| NONDEDUCTIBLE EXPENSES FROM PARTNERSHIPS | 999 | 0 | 0 | |
| PASSTHROUGH DEDUCTION UNDER SECTION 965(C) | 18 | 18 | 0 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| PARTNERSHIPS ORDINARY INCOME | -564 | -564 | -564 |
| PARTNERSHIPS ROYALTIES | 3 | 3 | 3 |
| PARTNERSHIPS OTHER PORTFOLIO INC | 73,197 | 73,197 | 73,197 |
| PARTNERSHIPS OTHER INCOME | 180,828 | 180,828 | 180,828 |
| PARTNERSHIPS RENTAL INCOME | -6,940 | -6,940 | -6,940 |
| PARTNERSHIPS SUBPART F INCOME | 11,379 | 11,379 | 11,379 |
| UNRELATED BUSINESS INCOME FROM PASSTHROUGH | -25,700 | -25,700 | |
| SECTION 965(A) INCOME INCLUSION | 36 | 36 | 36 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAXES WITHHELD FROM DIVIDENDS | 5,679 | 5,679 | 0 | |
| FOREIGN TAXES WITHHELD FROM PARTNERSHIP INCOME | 8,326 | 8,326 | 0 | |
| STATE EXCISE TAX | 133 | 0 | 0 |